SCHEMBL1186508

SCHEMBL1186508

Cc1cc(N2CCC(NC(=O)OC(C)(C)C)CC2)ccc1-c1nnc(C2(c3ccccc3)CC2)n1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
KCNA3 P22001 1/20 0.42
SUV39H2 Q9H5I1 4/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
BRD4 O60885 1/20 0.38
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
NSD2 O96028 1/20 0.38
HSD11B1 P28845 4/20 0.38
BTK Q06187 1/20 0.38
NR1I2 O75469 1/20 0.38
AKT1 P31749 2/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108757 0.92 CNR1 (0.46) CKS1BSKP1SKP2KCNA3SUV39H2
SCHEMBL1108832 0.83 CKS1B (0.49) CKS1BSKP1SKP2KCNA3CNR1
SCHEMBL13436637 0.80 HSD11B1 (0.49) HSD11B1NR1I2
SCHEMBL1108754 0.73 HSD11B1 (0.49) HSD11B1NR1I2
SCHEMBL1108759 0.73 HSD11B1 (0.49) HSD11B1NR1I2
SCHEMBL1108745 0.73 HSD11B1 (0.53) HSD11B1NR1I2
SCHEMBL17830852 0.72 CKS1B (0.61) CKS1BSKP1SKP2KCNA3PIM1
SCHEMBL1108801 0.72 HSD11B1 (0.49) HSD11B1NR1I2
SCHEMBL1108797 0.70 NOTUM (0.46) HSD11B1NR1I2
SCHEMBL1108751 0.70 HSD11B1 (0.61) HSD11B1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153631-B2 Triazole compounds and uses related thereto AMGEN INC. (US) 2012-04-10 US disclosed
US-20100062972-A1 TRIAZOLE COMPOUNDS AND USES RELATED THERETO AMGEN INC. 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100062972-A1 TRIAZOLE COMPOUNDS AND USES RELATED THERETO HSD11B1, HSD17B1, HSD17B3 CKS1B 1748/4885SKP1 2496/4885SKP2 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.